Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Unconjugated Hyperbilirubinemia

  • Author: Hisham Nazer, MB, BCh, FRCP, , DTM&H; Chief Editor: BS Anand, MD  more...
 
Updated: May 02, 2016
 

Practice Essentials

Unconjugated hyperbilirubinemia can result from increased production, impaired conjugation, or impaired hepatic uptake of bilirubin, a yellow bile pigment produced from hemoglobin during erythrocyte destruction.[1, 2] It can also occur naturally in newborns. Unless treated vigorously, most patients with Crigler-Najjar syndrome type 1, a form of unconjugated hyperbilirubinemia, die in early infancy.

The image below illustrates the production of bilirubin.

Production of bilirubin. Production of bilirubin.

Signs and symptoms

Signs/symptoms of unconjugated hyperbilirubinemia include the following:

  • Ineffective erythropoiesis (early labeled bilirubin [ELB] production) - Characterized by the onset of asymptomatic jaundice
  • Crigler-Najjar (CN) syndrome type 1 - Jaundice develops in the first few days of life and rapidly progresses by the second week; patients may present with evidence of kernicterus, the clinical manifestations of which are hypotonia, deafness, oculomotor palsy, lethargy and, ultimately, death
  • Crigler-Najjar syndrome type 2 - Usually, no clinical symptoms are reported with this disease entity
  • Gilbert syndrome - May manifest only as jaundice on clinical examination; at least 30% of patients with Gilbert syndrome are asymptomatic, although nonspecific symptoms, such as abdominal cramps, fatigue, and malaise, are common
  • Physiologic neonatal jaundice - Clinically obvious in 50% of neonates during the first 5 days of life
  • Nonphysiologic neonatal jaundice - Maternal serum jaundice, also known as Lucey-Driscoll syndrome, is an autosomal recessive metabolic disorder affecting enzymes involved in bilirubin metabolism; it causes a transient familial neonatal unconjugated hyperbilirubinemia, and jaundice occurs during the first 4 days of life

See Clinical Presentation for more detail.

Diagnosis

Crigler-Najjar syndrome type 1

Except for the presence of high serum unconjugated bilirubin levels, the results of liver tests in Crigler-Najjar syndrome type 1 are normal. Serum bilirubin levels range from 20-50 mg/dL. Conjugated bilirubin is absent from serum, and bilirubin is not present in urine. Definitive diagnosis of Crigler-Najjar syndrome requires high-performance liquid chromatography of bile or a tissue enzyme assay of a liver biopsy sample.

Crigler-Najjar syndrome type 2

Crigler-Najjar syndrome type 2 results in lower bilirubin concentrations than does type I, with levels ranging from 7-20 mg/dL.

Gilbert syndrome

As a rule, Gilbert syndrome can be diagnosed by a thorough history and physical examination and confirmed by standard blood tests. Laboratory results include the following:

  • Unconjugated hyperbilirubinemia noted on several occasions
  • Normal results of complete blood count (CBC), reticulocyte count, and blood smear
  • Normal liver function test (LFT) results
  • An absence of other disease processes

Specialized tests that have occasionally been used to confirm a diagnosis of Gilbert syndrome include the following:

  • Fasting test
  • Nicotinic acid test
  • Phenobarbital test
  • Radiolabeled chromium test
  • Thin-layer chromatography
  • Drug clearance test
  • Polymerase chain reaction (PCR) assay
  • Percutaneous liver biopsy - Very rarely performed

Physiologic neonatal jaundice

In physiologic jaundice, the peak total serum bilirubin level is 5-6 mg/dL (86-103 µmol/L), occurs at 48-120 hours of age, and does not exceed 17-18 mg/dL (291-308 µmol/L).

Breast milk jaundice

In breast milk jaundice, the bilirubin may increase to levels as high as 20 mg/dL, necessitating the need for phototherapy and the discontinuation of breastfeeding.

Ineffective erythropoiesis

This is characterized by a marked increase in fecal urobilinogen excretion and a normal or near-normal red blood cell lifespan.

See Workup for more detail.

Management

Crigler-Najjar syndrome type 1

  • Pharmacologic therapy - Administration of cholestyramine, calcium phosphate, oral agar, orlistat, and Sn-protoporphyrin [3, 4]
  • Repeated exchange transfusions
  • Long-term phototherapy
  • Plasmapheresis
  • Hemoperfusion
  • Liver transplantation - The only guaranteed form of therapy
  • Hepatocyte transplantation

Crigler-Najjar syndrome type 2

Patients with this disease may not require any treatment or can be managed with phenobarbital.

Gilbert syndrome

In light of the benign and inconsequential nature of Gilbert syndrome, the use of medications to treat patients with this condition is unjustified in clinical practice.

Neonatal jaundice

No treatment is needed for physiologic jaundice. For breast milk jaundice and other types of nonphysiologic jaundice, phototherapy can be used.

See Treatment and Medication for more detail.

Next

Background

Unconjugated hyperbilirubinemia can result from increased production, impaired conjugation, or impaired hepatic uptake of bilirubin, a yellow bile pigment produced from hemoglobin during erythrocyte destruction. It can also occur naturally in newborns. (See Pathophysiology and Etiology.)

Biochemistry of bilirubin

Bilirubin is a potentially toxic catabolic product of heme metabolism. There are elaborate physiologic mechanisms for its detoxification and disposition. Understanding these mechanisms is necessary for interpretation of the clinical significance of high serum bilirubin concentrations. (See Pathophysiology and Prognosis.)

In adults, 250-400 mg of bilirubin is produced daily. Approximately 70-80% of daily bilirubin is derived from the degradation of the heme moiety of hemoglobin. The remaining 20-25% is derived from the hepatic turnover of heme proteins, such as myoglobin, cytochromes, and catalase. A small portion of daily bilirubin is derived from the destruction of young or developing erythroid cells.

Bilirubin is poorly soluble in water at physiologic pH because of internal hydrogen bonding that engages all polar groups and gives the molecule an involuted structure. The fully hydrogen-bonded structure of bilirubin is designated bilirubin IX-alpha-ZZ. The intramolecular hydrogen bonding shields the hydrophilic sites of the bilirubin molecule, resulting in a hydrophobic structure. Water-insoluble, unconjugated bilirubin is associated with all known toxic effects of bilirubin. Thus, the internal hydrogen bonding is critical in producing bilirubin toxicity and also prevents its elimination.

Conversion of bilirubin IX-alpha to a water-soluble form by disruption of the hydrogen bonds is essential for its elimination by the liver and kidney. This is achieved by glucuronic acid conjugation of the propionic acid side chains of bilirubin. Bilirubin glucuronides are water-soluble and are readily excreted in bile. Bilirubin is primarily excreted in normal human bile as diglucuronide; unconjugated bilirubin accounts for only 1-4% of pigments in normal bile. (See the images below.)

Production of bilirubin. Production of bilirubin.
Enterohepatic circulation of bilirubin. Enterohepatic circulation of bilirubin.
Conjugation of bilirubin. Conjugation of bilirubin.

Increased production of bilirubin

Hemolysis generally induces a modest elevation in plasma levels of unconjugated bilirubin (1-4 mg/dL). During acute hemolytic crises, such as those occurring in sickle cell disease or paroxysmal nocturnal hemoglobinuria, bilirubin production and plasma bilirubin may transiently exceed these levels. Although the plasma bilirubin level increases linearly in relation to bilirubin production, the bilirubin concentration may still be near the reference range in patients with a 50% reduction in red blood cell survival if hepatic bilirubin clearance is within the reference range.

Ineffective erythropoiesis (early labeled bilirubin [ELB] production) that is markedly increased is the basis of a rare disorder known as primary shunt hyperbilirubinemia, or idiopathic dyserythropoietic jaundice.

Impaired hepatic bilirubin uptake

The hepatic uptake of bilirubin can be reduced by the following:

  • Congestive heart failure
  • Surgical/naturally occurring shunts
  • Drugs/contrast agents

Unconjugated hyperbilirubinemia due to drugs/contrast agents resolves within 48 hours of discontinuing the drug; agents that can cause the condition include rifampicin, rifamycin, probenecid, flavaspidic acid, and bunamiodyl (cholecystographic agent).

Neonatal jaundice

Physiologic jaundice

All newborns have higher bilirubin levels (mainly unconjugated bilirubin) than do adults.

Nonphysiologic jaundice

This includes breast milk jaundice, also known as maternal milk jaundice (breastfed infants have higher mean bilirubin levels than do formula-fed infants),[5] and maternal serum jaundice, also known as Lucey-Driscoll syndrome.

ABO/Rh incompatibility

Neonatal jaundice can also result from an increased bilirubin load or from ABO/Rh incompatibility. With regard to the latter, incompatibility can have the following causes:

  • Inherited red blood cell disorders - Sickle cell disease and hereditary spherocytosis/ elliptocytosis
  • Drug reactions
  • Ineffective erythropoiesis - Thalassemia, vitamin B-12 deficiency, and congenital dyserythropoietic anemia

Impaired conjugation of bilirubin

The following inherited defects of bilirubin conjugation are known to exist in humans:

  • Crigler-Najjar syndrome types 1 and 2
  • Gilbert syndrome

Gilbert syndrome is believed to affect approximately 3-7% of the adult population. Crigler-Najjar syndrome is a much rarer disorder, with only a few hundred cases described in the literature. (See Epidemiology.)

Crigler-Najjar syndrome

First described by Crigler and Najjar in 1952, Crigler-Najjar syndrome is a congenital, familial, nonhemolytic jaundice associated with high levels of unconjugated bilirubin. The original report described 6 infants from 3 related families with severe unconjugated hyperbilirubinemia, which was recognized shortly after birth. (See Prognosis.)

Five of the children died by age 15 months of kernicterus, a potentially fatal disorder affecting the basal ganglia and other parts of the central nervous system. The remaining patient died at age 15 years, several months after suffering a devastating brain injury.[6] (Activation of astrocytes by unconjugated hyperbilirubinemia is believed to play a major part in kernicterus via the production of inflammatory cytokines.[7] )

Crigler-Najjar syndrome is a rare disorder caused by an impairment of bilirubin metabolism resulting in a deficiency or complete absence of hepatic microsomal bilirubin-uridine diphosphate glucuronosyltransferase (bilirubin-UGT) activity. (See Pathophysiology and Etiology.)

Two distinct forms of Crigler-Najjar syndrome are as follows:

  • Crigler-Najjar syndrome type 1 - Associated with neonatal unconjugated hyperbilirubinemia (high levels) and kernicterus
  • Crigler-Najjar syndrome type 2 (also called Arias syndrome) - Presents with a lower serum bilirubin level; responds to phenobarbital treatment

Type 1 is an autosomal recessive disorder, while the mode of inheritance for Crigler-Najjar syndrome type 2 is still not clear. Autosomal dominant transmission with variable penetrance and autosomal recessive transmission have both been reported for type 2.

Over the past decades, progress has been made in the diagnosis and treatment of Crigler-Najjar syndrome. Phototherapy was long recognized as a form of treatment,[8] and in 1986, liver transplantation was shown to be curative.[9] In 1992, the locus of the missing gene behind this disorder was identified. (See Clinical Presentation, Workup, Treatment, and Medication.)[10, 11]

Gilbert syndrome

Gilbert syndrome is a benign, familial disorder inherited in an autosomal recessive pattern characterized by intermittent jaundice in the absence of hemolysis or underlying liver disease. The condition is recognized to arise from a mutation in the promoter region of the UGT1A1 gene, which results in reduced UGT production. (See Pathophysiology and Etiology.)

Also called constitutional hepatic dysfunction or familial nonhemolytic jaundice, Gilbert syndrome is the mildest form of inherited, nonhemolytic unconjugated hyperbilirubinemia.[12] The most common inherited cause of unconjugated hyperbilirubinemia, it occurs in 3-7% of the world’s population. (See Epidemiology.)

By definition, bilirubin levels in Gilbert syndrome are lower than 6 mg/dL, though most patients exhibit levels lower than 3 mg/dL. Considerable daily and seasonal variations are observed, and in as many as one third of patients, the bilirubin levels occasionally may be normal.

Gilbert syndrome may be precipitated by dehydration, fasting, menstrual periods, or other causes of stress, such as an intercurrent illness or vigorous exercise.[13] Patients may report vague abdominal discomfort and general fatigue for which no cause is found. These episodes typically resolve spontaneously without curative treatment.

As a rule, Gilbert syndrome can be diagnosed with a thorough history and physical examination and can be confirmed with standard blood tests. Repeated investigations and invasive procedures are not usually justified for establishing a diagnosis. (See Clinical Presentation and Workup.)

Once the diagnosis of Gilbert syndrome is established, the most important aspect of treatment is reassurance. In light of the benign and inconsequential nature of the syndrome, the use of medications to treat patients with this condition is unjustified in clinical practice. (See Treatment and Medication.)

Previous
Next

Pathophysiology

Unconjugated bilirubin is transported in the plasma bound to albumin. At the sinusoidal surface of the liver, unconjugated bilirubin detaches from albumin and is transported through the hepatocyte membrane by facilitated diffusion. Within the hepatocyte, bilirubin is bound to 2 major intracellular proteins: cytosolic Y protein (ie, ligandin or glutathione S-transferase B) and cytosolic Z protein (also known as fatty acid–binding protein [FABP]). The binding of bilirubin to these proteins decreases the efflux of bilirubin back into the plasma and, therefore, increases net bilirubin uptake. (See the image below.)

Enterohepatic circulation of bilirubin. Enterohepatic circulation of bilirubin.

In order for bilirubin to be excreted into bile and, therefore, eliminated from the body, it must be made more soluble. This water-soluble, or conjugated, form of bilirubin is produced when glucuronic acid enzymatically is attached to 1 or both of the propionic side chains of bilirubin IX-alpha (ZZ). Enzyme-catalyzed glucuronidation is one of the most important detoxification mechanisms of the body. Of the various isoforms of the UGT family of enzymes, only 1 of them, bilirubin-UGT1A1, is physiologically important in bilirubin glucuronidation.

UGT enzymes are normally concentrated in the lipid bilayer of the endoplasmic reticulum of hepatocytes, intestinal cells, kidneys, and other tissues.

Attachment of glucuronic acid to bilirubin occurs through an ester linkage and, therefore, is called esterification. This esterification is catalyzed by bilirubin-UGT, which is located in the endoplasmic reticulum of the hepatocyte. This reaction leads to the production of water-soluble bilirubin monoglucuronide and bilirubin diglucuronide. Other compounds, such as xylose and glucose, also can undergo esterification with bilirubin.

Bilirubin diglucuronide is the predominant pigment in healthy adult human bile, representing over 80% of the pigment. However, in subjects with reduced bilirubin-UGT activity, the proportion of bilirubin diglucuronide decreases, and bilirubin monoglucuronide may constitute more than 30% of the conjugates excreted in bile.

Increased production of bilirubin

In a review of 11 cases of ineffective erythropoiesis (early labeled bilirubin [ELB] production), evidence existed of rapid heme and hemoglobin turnover in the bone marrow, possibly due to premature destruction of red blood cell precursors. These patients also had erythroid hyperplasia of bone marrow, reticulocytosis, increased iron turnover with diminished red blood cell incorporation, and hemosiderosis of hepatic parenchymal cells and Kupffer cells. The underlying defect responsible for the high rate of heme turnover within the marrow remains unknown.

Neonatal jaundice

Hyperbilirubinemia may reach or exceed 10 mg/dL in approximately 16% of newborns. In a study of genetic risk factors in 35 breastfed term infants with prolonged unconjugated hyperbilirubinemia, Chang et al found that 29 of the infants had 1 or more UGT1A1 mutations, with variation at nucleotide 211 being the most common.[14] Moreover, a significantly higher percentage of these neonates possessed the variant nucleotide 211 than did the control group (n=90). The authors also found that the risk of prolonged hyperbilirubinemia was higher in the male infants than in the female neonates.

In a study involving 126 Indian infants with hyperbilirubinemia, de Silva et al found an association between single-nucleotide polymorphisms (SNPs) of both the UGT1A1 and OATP2 genes and altered bilirubin metabolism, suggesting these polymorphisms may be possible risk factors for neonatal hyperbilirubinemia.[15]

Physiologic jaundice

Physiologic jaundice is a mild unconjugated hyperbilirubinemia that affects nearly all newborns and resolves within the first several weeks after birth. It has been shown that bilirubin production in a term newborn is 2-3 times higher than in adults. It is caused by increased bilirubin production, decreased bilirubin clearance, and increased enterohepatic circulation. The following factors contribute to the development of physiologic jaundice:

  • Inefficient hepatic excretion of unconjugated bilirubin
  • Portal venous shunting through a patent ductus venosus
  • Shortened red blood cell survival
  • Immaturity of hepatic bilirubin clearance - Bilirubin-UGT activity is only 1% of normal adult levels at birth, regardless of gestational age; enzyme activity increases to adult levels by the 14th week of life; the main precipitant factors are decreased energy intake and delayed closure of the ductus venosus
  • Hydrolysis of conjugated bilirubin - The activity of beta-glucuronidase is increased in newborns, which leads to greater hydrolysis of conjugated bilirubin to the unconjugated form; the unconjugated bilirubin is reabsorbed from the intestine through the process of enterohepatic circulation
  • Low bacterial degradation of bilirubin - In neonates, the bacterial degradation of bilirubin is reduced because intestinal flora is not fully developed; this may lead to increased absorption of unconjugated bilirubin

Bilirubin and drug metabolism in neonates can also be affected by the influences of ethnicity on UGT1A1 haplotype mutations.[16] A cohort study of 241 consecutive term Asian infants reported that not only was there a variance in the prevalence of hypomorphic haplotypes, but also that the frequency varied between the different races.[17] For example, Indian neonates were more likely to have at least 1 hydromorphic haplotype (64%) than were Chinese (48%) and Malay (31%) neonates. There was also a trend between the number of G71R mutations and the need for phototherapy.

The peak total serum bilirubin level in physiologic jaundice typically is 5-6 mg/dL (86-103 µmol/L), occurs 48-120 hours after birth, and does not exceed 17-18 mg/dL (291-308 µmol/L). Higher levels of unconjugated hyperbilirubinemia are pathologic and occur in various conditions.

Nonphysiologic jaundice

Breast milk (maternal milk) jaundice results from increased enterohepatic circulation. It is thought to result from an unidentified component of human milk that enhances intestinal absorption of bilirubin. One possible mechanism for hyperbilirubinemia in breastfed infants is the increased concentration of beta-glucuronidase in breast milk. Beta-glucuronidase deconjugates intestinal bilirubin, increasing its ability to be absorbed (ie, increasing enterohepatic circulation).

Maternal serum jaundice (Lucey-Driscoll syndrome) may result from the presence of an unidentified inhibitor of UGT, which enters the fetus through maternal serum.

Impaired conjugation of bilirubin

Deficiency of bilirubin-UGT leads to ineffective esterification of bilirubin, which in turn results in an unconjugated hyperbilirubinemia. Reduced bilirubin conjugation as a result of a decreased or absent UGT activity is found in several acquired conditions and inherited diseases, such as Crigler-Najjar syndrome (types I and II) and Gilbert syndrome. Bilirubin conjugating activity is also very low in the neonatal liver. An illustration of bilirubin conjugation is shown in the image below.

Conjugation of bilirubin. Conjugation of bilirubin.

UGT activity toward bilirubin is modulated by various hormones. Excess thyroid hormone and ethinyl estradiol, but not other oral contraceptives, inhibit bilirubin glucuronidation. In comparison, the combination of progestational and estrogenic steroids results in increased enzyme activity.

Bilirubin glucuronidation can also be inhibited by certain antibiotics (eg, novobiocin or gentamicin at serum concentrations exceeding therapeutic levels) and by chronic hepatitis, advanced cirrhosis, and Wilson disease.[18]

Crigler-Najjar syndrome

One or more mutations in any 1 or more of the 5 exons of the gene that codes for UGT 1A1 can cause Crigler-Najjar syndrome.[19, 20, 21, 22] More than 50 mutations that cause Gilbert syndrome and Crigler-Najjar syndrome have been identified, most of which are missense or nonsense mutations.

Depending on the severity of a mutation’s effect on the enzymatic activity, Crigler-Najjar syndrome type 1 (a complete absence of enzymatic activity) or Crigler-Najjar syndrome type 2 (UGT level < 10% of normal) may result. The differentiation between type 1 and 2 is not always easy, and both types are quite possibly different expressions of a single disease.

Gilbert syndrome

Hepatic bilirubin UGT activity is consistently decreased to approximately 30% of normal in individuals with Gilbert syndrome. Decreased bilirubin-UGT activity has been attributed to an expansion of thymine-adenine (TA) repeats in the promoter region of the UGT-1TA gene. Racial variation in the number of TA repeats and a correlation with enzyme activity suggest that these polymorphisms contribute to variations in bilirubin metabolism. An increased proportion of the bilirubin monoconjugates in bile reflects reduced transferase activity.[14, 23, 24, 25]

Fasting, febrile illness, alcohol, or exercise can exacerbate jaundice in patients with Gilbert syndrome. Hemolysis and mild icterus usually occur at times of stress, starvation, and infection.

Investigators have discovered that Gilbert syndrome may coexist with other liver diseases, such as nonalcoholic steatohepatitis. Therefore, unconjugated hyperbilirubinemia in patients with these other conditions may be due to Gilbert syndrome and should not always be attributed to the underlying liver disorder.

UGT mutations in Gilbert syndrome

Bilirubin-UGT, which is located primarily in the endoplasmic reticulum of hepatocytes, is responsible for conjugating bilirubin into bilirubin monoglucuronides and diglucuronides. It is one of several UGT enzyme isoforms responsible for the conjugation of a wide array of substrates, including carcinogens, drugs, hormones, and neurotransmitters.

Knowledge of these enzymes has been enhanced greatly by characterization of the UGT1 gene locus in humans. The gene that expresses bilirubin-UGT has a complex structure and is located on chromosome 2.[23, 26, 27, 28, 29, 30, 31] There are 5 exons, of which exons 2-5, at the 3' end, are constant components of all isoforms of UGT, coding for the uridine diphosphate (UDP)-glucuronic acid binding site. Exon 1 encodes for a unique region within each UGT and confers substrate specificity; exon 1a encodes the variable region for bilirubin UGT1A1. Defects in the UGT1A1 enzyme are responsible for Gilbert syndrome and for Crigler-Najjar syndrome.[32, 33]

Expression of UGT1A1 depends on a promoter region in a 5' position relative to each exon 1 that contains a TATAA box. Impaired bilirubin glucuronidation therefore may result from mutations in exon 1a, its promoter, or the common exons.

A breakthrough in understanding the genetic basis of Gilbert syndrome was achieved in 1995, when abnormalities in the TATAA region of the promoter were identified. The addition of 2 extra bases (TA) to the TATAA region interferes with the binding of transcription factor IID and results in reduced expression of bilirubin-UGT1 (30% of normal). In the homozygous state, diminished bilirubin glucuronidation is observed, with bile containing an excess of bilirubin monoglucuronide over diglucuronide.[26, 34, 35, 36, 37]

Insertion of a homozygous TA dinucleotide in the regulatory TATA box in the UGT 1A1 gene promoter is the most common genetic defect in Gilbert syndrome.[7]

In Gilbert syndrome, the UGT1A1*28 variant reduces bilirubin conjugation by 70% and is associated with irinotecan and protease inhibitor side effects. In vivo research into the genotype present in 76% of individuals with Gilbert syndrome suggests that transcription and transcriptional activation of glucuronidation genes responsible for conjugation and detoxification are directly affected, leading to lower responsiveness.[31]

Additional mutations have since been identified. For example, some healthy Asian patients with Gilbert syndrome do not have mutations at the promoter level but are heterozygotes for missense mutations (Gly71Arg, Tyr486Asp, Pro364Leu) in the coding region. These individuals also have significantly higher bilirubin levels than do patients with the wild-type allele.

Whether reduced bilirubin-UGT activity results from a reduced number of enzyme molecules or from a qualitative enzyme defect is unknown. To compound this uncertainty, other factors (eg, occult hemolysis or hepatic transport abnormalities) may be involved in the clinical expression of Gilbert syndrome. For example, many individuals who are homozygous for the TATAA defect do not demonstrate unconjugated hyperbilirubinemia, and many patients with reduced levels of bilirubin-UGT, as observed in some granulomatous liver diseases, do not develop hyperbilirubinemia.

Because of the high frequency of mutations in the Gilbert promoter, heterozygous carriers of Crigler-Najjar syndromes types 1 and 2 can also carry the elongated Gilbert TATAA sequence on their normal allele. Such combined defects can lead to severe hyperbilirubinemia and help to explain the finding of intermediate levels of hyperbilirubinemia in family members of patients with Crigler-Najjar syndrome.

Gilbert syndrome can also frequently coexist with conditions associated with unconjugated hyperbilirubinemia, such as thalassemia[38] and glucose-6-phosphate deficiency (G6PD).[39, 40] Much of the observed unconjugated hyperbilirubinemia could be attributed to variation at the UGT 1A1 locus.[41]

Origa et al, in a study of 858 patients with transfusion-dependent thalassemia, found that in individuals with a combination of thalassemia and the Gilbert syndrome genotype (TA)7/(TA)7 UGT1A1, the latter effected the prevalence of cholelithiasis and influenced the age at which the condition arose.[42] The authors suggested that in patients with a combination of thalassemia and Gilbert syndrome, biliary ultrasonography should be performed, starting in childhood.

A Greek study of 198 adult patients with cholelithiasis, along with 152 controls, also found evidence of an association between Gilbert syndrome and the development of cholelithiasis.[43]

Previous
Next

Etiology

Increased bilirubin production can result from the following:

  • Hemolysis
  • Dyserythropoiesis
  • Hematoma

Impaired hepatic bilirubin uptake can result from the following:

  • Congestive heart failure
  • Portosystemic shunts
  • Drugs - Rifamycin, rifampin, probenecid

Impaired bilirubin conjugation can result from the following:

  • Crigler-Najjar syndrome types I and II
  • Gilbert syndrome (decreased uptake and/or conjugation)
  • Neonatal physiologic jaundice
  • Breast milk jaundice
  • Maternal serum jaundice
  • Hypothyroidism/hyperthyroidism
  • Ethinyl estradiol
  • Liver diseases - Chronic hepatitis, cirrhosis, and Wilson disease
Previous
Next

Epidemiology

Occurrence in the United States

There have been less than 50 known cases of Crigler-Najjar syndrome in the United states, and only a few hundred cases have been described in the world literature.[44] In the United States, the prevalence of Gilbert syndrome is 3-7%.

Breast milk jaundice affects approximately 0.5-2.4% of live births. There is a familial incidence of 13.9%, indicating that, in some cases, a unique genetic factor may be expressed.

International occurrence

Crigler-Najjar syndrome is a rare disease. The estimated incidence is 1 case per 1,000,000 births, with only several hundred people worldwide having been reported to have this disease. The syndrome is mostly encountered in communities where high rates of consanguineous marriages prevail.

The prevalence of Gilbert syndrome varies considerably around the world, depending on which diagnostic criteria are used (eg, number of bilirubin determinations, method of analysis, bilirubin levels used for diagnosis, whether the patient was fasting). Estimates of prevalence may be complicated further by molecular genetic studies of polymorphisms in the TATAA promoter region, which affect as many as 36% of Africans but only 3% of Asians.

Race-related demographics

In Gilbert syndrome, differences exist in the mutation of the UGT1A1 gene in certain ethnic groups; the TATAA element in the promoter region is the most common mutation site in the Caucasian population.

A racial variation exists in the development of neonatal jaundice. A common mutation in the UGT gene (Gly71Arg) leads to an increased incidence of severe neonatal hyperbilirubinemia (approximately 20%) in Asians.

Sex-related demographics

Gilbert syndrome is diagnosed more commonly in boys after puberty than in girls. The apparent sex difference is due to the fact that daily bilirubin production is lower in women than in men. The male-to-female ratio for Gilbert syndrome ranges from 2:1 to 7:1.

Crigler-Najjar syndrome occurs in both sexes equally, while neonatal physiologic jaundice occurs more frequently in males.

Age-related demographics

The age at which symptoms of unconjugated hyperbilirubinemia appear varies as follows:

  • Crigler-Najjar syndrome type 1 - Symptoms appear within the first few days of life [45]
  • Crigler-Najjar syndrome type 2 - Symptoms may present later than they do in type 1; patients have jaundice during the first few years of life.
  • Gilbert syndrome – This is usually diagnosed around puberty, possibly because of the inhibition of bilirubin glucuronidation by endogenous steroid hormones
  • Physiologic jaundice affects nearly all newborns, occurs in the first 2-5 days following birth, and resolves within the first several weeks after birth.
  • Breast milk jaundice typically begins after the first 3-5 days, peaks within 2 weeks after birth, and progressively declines to normal levels over 3-12 weeks.
  • Ineffective erythropoiesis (ELB production) - This condition usually emerges at age 20-30 years
Previous
Next

Prognosis

Neonatal jaundice

Breast milk jaundice

The prognosis in this condition is excellent. The jaundice may continue for 4 weeks but promptly resolves when breastfeeding is discontinued. Even so, the bilirubin level needs to be closely monitored, with adjustments in care made accordingly to prevent persistent hyperbilirubinemia and its potential complications (ie, kernicterus in the fragile neonatal period).

However, late neurodevelopment or hearing defects have not been observed in neonates, thus enabling the pediatrician to encourage continuation of breastfeeding in most cases of healthy infants with breast milk jaundice.

Maternal serum jaundice

The prognosis in maternal serum jaundice is good, but jaundice can persist for several weeks. This entity is occasionally associated with kernicterus.

Impaired conjugation of bilirubin

Crigler-Najjar syndrome type 1

Kernicterus in infancy or later in life is the main cause of death in Crigler-Najjar syndrome type 1. This disease can also result in permanent neurologic sequelae, due to bilirubin encephalopathy. Even with treatment, most, if not all, patients with Crigler-Najjar (CN) syndrome type 1 eventually develop some neurologic deficit.

Unless treated vigorously (ie, orthotopic liver transplant, segmental transplantation), most patients with Crigler-Najjar syndrome type 1 die by age 15 months. Fortunately, more patients are surviving to adulthood because of advances in the treatment of hyperbilirubinemia.

Neonates of mothers with Crigler-Najjar syndrome type 1 develop adverse outcomes, including developmental delay, hearing loss, and cerebellar syndrome.[46]

Crigler-Najjar syndrome type 2

Although the type 2 form of this disease runs a more benign clinical course than type 1, several cases of bilirubin-induced brain damage have been reported. (Bilirubin encephalopathy occurs usually when patients experience a superimposed infection or stress.) With proper treatment, however, neurologic sequelae can be avoided.

In neonates of mothers with Crigler-Najjar syndrome type 2, the use of phenobarbital in pregnancy appears to be safe, with good fetal and maternal outcome.[46]

Gilbert syndrome

Gilbert syndrome is a common and benign condition. The bilirubin disposition may be regarded as falling within the range of normal biologic variation. The syndrome has no deleterious associations and an excellent prognosis, and affected persons can lead a normal lifestyle. As further confirmation of its benign nature, studies have reported excellent results in patients undergoing living-donor liver transplantation from donors with Gilbert syndrome.[47, 48]

Epidemiologic studies have reported an association between Gilbert syndrome, hyperbilirubinemia, and a reduced risk of cardiovascular disease.[49, 50] The exact mechanism for this finding is unclear, but the antioxidant properties of bilirubin may be contributory in conjunction with heme oxygenase. (See the image below.)[51, 52, 53]

Production of bilirubin. Production of bilirubin.

Clinicians need to be aware that patients with Gilbert syndrome may be at higher risk of developing toxicity from certain medications (eg, irinotecan) and protease inhibitors (eg, atazanavir, indinavir) that can inhibit UGT metabolism.[54] A study by Lankisch et al reported that the risk of severe hyperbilirubinemia with indinavir was associated with genetic variants of UGT1A3 and UGT1A7 genes in addition to Gilbert syndrome (UGT1A1*28).[55]

Kweekel et al reported that patients who were more likely to develop side effects of irinotecan toxicity, such as life-threatening neutropenia and diarrhea, were more likely to have underlying liver disease, hepatic conjugation disorders, or UGT1A1*28 genotype.[56] However, due to a lack of prospective data, the relationship between the UGT1A1 genotype and irinotecan toxicity remains unclear, although the irinotecan product label recommends reducing the irinotecan dose in patients with this genotype.

Increased production of bilirubin

The prognosis for ineffective erythropoiesis (ELB production) appears to be excellent. Similar to other causes of enhanced bilirubin production, however, it predisposes patients to cholelithiasis.

Previous
Next

Patient Education

Educate patients and families about the chronicity of the disease and the need for lifelong treatment. Instruct them to immediately report any change in the patient's mental or neurologic status.

Genetic counseling is recommended for prospective parents with a family history of Crigler-Najjar syndrome.

For patient education information, see the Digestive Disorders Center and the Infections Center, as well as Cirrhosis and Newborn Jaundice.

Previous
 
 
Contributor Information and Disclosures
Author

Hisham Nazer, MB, BCh, FRCP, , DTM&H Professor of Pediatrics, Consultant in Pediatric Gastroenterology, Hepatology and Clinical Nutrition, University of Jordan Faculty of Medicine, Jordan

Hisham Nazer, MB, BCh, FRCP, , DTM&H is a member of the following medical societies: American Association for Physician Leadership, Royal College of Paediatrics and Child Health, Royal College of Surgeons in Ireland, Royal Society of Tropical Medicine and Hygiene, Royal College of Physicians and Surgeons of the United Kingdom

Disclosure: Nothing to disclose.

Coauthor(s)

Praveen K Roy, MD, AGAF Chief of Gastroenterology, Presbyterian Hospital; Medical Director of Endoscopy, Presbyterian Medical Group; Adjunct Associate Research Scientist, Lovelace Respiratory Research Institute

Praveen K Roy, MD, AGAF is a member of the following medical societies: American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Additional Contributors

Ann Ouyang, MBBS Professor, Department of Internal Medicine, Pennsylvania State University College of Medicine; Attending Physician, Division of Gastroenterology and Hepatology, Milton S Hershey Medical Center

Disclosure: Nothing to disclose.

Julian Katz, MD Clinical Professor of Medicine, Drexel University College of Medicine

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Acknowledgements

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Showkat Bashir, MD Assistant Professor, Department of Medicine, Division of Gastroenterology, George Washington University, Washington, DC

Showkat Bashir, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, and American Medical Association

Disclosure: Nothing to disclose.

David Eric Bernstein, MD Director of Hepatology, North Shore University Hospital; Professor of Clinical Medicine, Albert Einstein College of Medicine

David Eric Bernstein, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Manoop S Bhutani, MD Professor, Co-Director, Center for Endoscopic Research, Training and Innovation (CERTAIN), Director, Center for Endoscopic Ultrasound, Department of Medicine, Division of Gastroenterology, University of Texas Medical Branch; Director, Endoscopic Research and Development, The University of Texas MD Anderson Cancer Center

Manoop S Bhutani, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Institute of Ultrasound in Medicine, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Jack Bragg, DO Associate Professor, Department of Clinical Medicine, University of Missouri School of Medicine

Jack Bragg, DO is a member of the following medical societies: American College of Osteopathic Internists and American Osteopathic Association

Disclosure: Nothing to disclose.

Annie T Chemmanur, MD Attending Physician, Metrowest Medical Center and University of Massachusetts Memorial Hospital, Marlborough Campus

Annie T Chemmanur, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Gastroenterological Association, American Medical Association, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

Carmen Cuffari, MD Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine

Carmen Cuffari, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Gautam Dehadrai, MD Department Chair, Section Chief, Department of Interventional Radiology, Norman Regional Hospital

Gautam Dehadrai, MD is a member of the following medical societies: American College of Radiology, Medical Council of India, and Radiological Society of North America

Disclosure: Nothing to disclose.

Jayant Deodhar, MD Associate Professor in Pediatrics, BJ Medical College, India; Honorary Consultant, Departments of Pediatrics and Neonatology, King Edward Memorial Hospital, India

Disclosure: Nothing to disclose.

Shirley Donelson, MD Program Director, Assistant Professor, Department of Internal Medicine, Division of Digestive Diseases, University of Mississippi Medical School

Shirley Donelson, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Medical Association, and Mississippi State Medical Association

Disclosure: Nothing to disclose.

Sandeep Mukherjee, MB, BCh, MPH, FRCPC Associate Professor, Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Nebraska Medical Center; Consulting Staff, Section of Gastroenterology and Hepatology, Veteran Affairs Medical Center

Disclosure: Merck Honoraria Speaking and teaching; Ikaria Pharmaceuticals Honoraria Board membership

Dena Nazer, MD Medical Director, Child Protection Center, Children's Hospital of Michigan; Assistant Professor, Wayne State University

Dena Nazer, MD is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, American Professional Society on the Abuse of Children, and Helfer Society

Disclosure: Nothing to disclose.

Mohamed Othman, MD Resident Physician, Department of Internal Medicine, University of New Mexico School of Medicine

Disclosure: Nothing to disclose.

Nuri Ozden, MD Assistant Professor, Department of Internal Medicine, Meharry Medical College

Nuri Ozden, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Tushar Patel, MB, ChB Professor of Medicine, Ohio State University Medical Center

Tushar Patel, MB, ChB is a member of the following medical societies: American Association for the Study of Liver Diseases and American Gastroenterological Association

Disclosure: Nothing to disclose.

David A Piccoli, MD Chief of Pediatric Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia; Professor, University of Pennsylvania School of Medicine

David A Piccoli, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association, and North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Nothing to disclose.

Alessio Pigazzi, MD PhD, Head, Minimally Invasive Surgery Program, Division of Surgery, Department of General Oncologic Surgery, City of Hope National Medical Center

Disclosure: Nothing to disclose.

Praveen K Roy, MD, AGAF Gastroenterologist, Ochsner Clinic Foundation; Adjunct Associate Research Scientist, Lovelace Respiratory Research Institute; Editor-in-Chief, The Internet Journal of Gasteroenterology; Editorial Board, Signal Transduction Insights; Editorial Board, The Internet Journal of Epidemiology; Editorial Board, Gastrointestinal Endoscopy Review Letter

Praveen K Roy, MD, AGAF is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, and American Society of Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Jeanette G Smith, MD Fellow, Department of Gastroenterology-Hepatology, University of Connecticut School of Medicine

Jeanette G Smith, MD is a member of the following medical societies: American College of Physicians, American Gastroenterological Association, and American Public Health Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

George Y Wu, MD, PhD Professor, Department of Medicine, Director, Hepatology Section, Herman Lopata Chair in Hepatitis Research, University of Connecticut School of Medicine

George Y Wu, MD, PhD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association, American Medical Association, American Society for Clinical Investigation, and Association of American Physicians

Disclosure: Springer Consulting fee Consulting; Gilead Consulting fee Review panel membership; Vertex Honoraria Speaking and teaching; Bristol-Myers Squibb Honoraria Speaking and teaching; Springer Royalty Review panel membership; Merck Honoraria Speaking and teaching

References
  1. Memon N, Weinberger BI, Hegyi T, Aleksunes LM. Inherited disorders of bilirubin clearance. Pediatr Res. 2015 Nov 23. [Medline].

  2. Dani C, Pratesi S, Raimondi F, Romagnoli C, for the Task Force for Hyperbilirubinemia of the Italian Society of Neonatology. Italian guidelines for the management and treatment of neonatal cholestasis. Ital J Pediatr. 2015 Oct 1. 41:69. [Medline].

  3. Hafkamp AM, Nelisse-Haak R, Sinaasappel M, Oude Elferink RP, Verkade HJ. Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: a randomized controlled trial. Pediatr Res. 2007 Dec. 62(6):725-30. [Medline].

  4. Sisson TR, Drummond GS, Samonte D, Calabio R, Kappas A. Sn-protoporphyrin blocks the increase in serum bilirubin levels that develops postnatally in homozygous Gunn rats. J Exp Med. 1988 Mar 1. 167(3):1247-52. [Medline]. [Full Text].

  5. Smith JR, Donze A, Schuller L. An evidence-based review of hyperbilirubinemia in the late preterm infant, with implications for practice: management, follow-up, and breastfeeding support. Neonatal Netw. 2007 Nov-Dec. 26(6):395-405. [Medline].

  6. Lucey JF, Suresh GK, Kappas A. Crigler-Najjar syndrome, 1952-2000: learning from parents and patients about a very rare disease and using the internet to recruit patients for studies. Pediatrics. 2000 May. 105(5):1152-3. [Medline].

  7. Falcão AS, Silva RF, Fernandes A, Brito MA, Brites D. Influence of hypoxia and ischemia preconditioning on bilirubin damage to astrocytes. Brain Res. 2007 May 29. 1149:191-9. [Medline].

  8. Nydegger A, Bednarz A, Hardikar W. Use of daytime phototherapy for Crigler-Najjar disease. J Paediatr Child Health. 2005 Jul. 41(7):387-9. [Medline].

  9. Morioka D, Kasahara M, Takada Y, Corrales JP, Yoshizawa A, Sakamoto S, et al. Living donor liver transplantation for pediatric patients with inheritable metabolic disorders. Am J Transplant. 2005 Nov. 5(11):2754-63. [Medline].

  10. Bosma PJ, Chowdhury NR, Goldhoorn BG, Hofker MH, Oude Elferink RP, Jansen PL, et al. Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology. 1992 May. 15(5):941-7. [Medline].

  11. Toietta G, Mane VP, Norona WS, Finegold MJ, Ng P, McDonagh AF, et al. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A. 2005 Mar 15. 102(11):3930-5. [Medline]. [Full Text].

  12. Fretzayas A, Moustaki M, Liapi O, Karpathios T. Gilbert syndrome. Eur J Pediatr. 2012 Jan. 171(1):11-5. [Medline].

  13. Lopardo G, Bissio E, Espinola L, Gallego P, Stambullian M, Gadano A. Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study. AIDS Res Hum Retroviruses. 2013 Mar. 29(3):456-60. [Medline]. [Full Text].

  14. Chang PF, Lin YC, Liu K, Yeh SJ, Ni YH. Prolonged unconjugated hyperbiliriubinemia in breast-fed male infants with a mutation of uridine diphosphate-glucuronosyl transferase. J Pediatr. 2009 Dec. 155(6):860-3. [Medline].

  15. D'Silva S, Colah RB, Ghosh K, Mukherjee MB. Combined effects of the UGT1A1 and OATP2 gene polymorphisms as major risk factor for unconjugated hyperbilirubinemia in Indian neonates. Gene. 2014 Aug 15. 547(1):18-22. [Medline].

  16. Saeki M, Saito Y, Sai K, Maekawa K, Kaniwa N, Sawada J, et al. A combinatorial haplotype of the UDP-glucuronosyltransferase 1A1 gene (#60-#IB) increases total bilirubin concentrations in Japanese volunteers. Clin Chem. 2007 Feb. 53(2):356-8. [Medline].

  17. Zhou YY, Lee LY, Ng SY, Hia CP, Low KT, Chong YS, et al. UGT1A1 haplotype mutation among Asians in Singapore. Neonatology. 2009. 96(3):150-5. [Medline].

  18. Saito A, Kawamoto M, Kamatani N. Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects. J Hum Genet. 2009 Jun. 54(6):317-23. [Medline].

  19. Servedio V, d'Apolito M, Maiorano N, Minuti B, Torricelli F, Ronchi F, et al. Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome patients: identification of twelve novel alleles and genotype-phenotype correlation. Hum Mutat. 2005 Mar. 25(3):325. [Medline].

  20. Jansen PL. Diagnosis and management of Crigler-Najjar syndrome. Eur J Pediatr. 1999 Dec. 158 Suppl 2:S89-94. [Medline].

  21. Stevenson DK, Vreman HJ, Wong RJ. Bilirubin production and the risk of bilirubin neurotoxicity. Semin Perinatol. 2011 Jun. 35(3):121-6. [Medline].

  22. Liu WL, Li F, He ZX, Jiang HY, Ai R, Chen XX, et al. Analysis of bilirubin UDP-glucuronosyltransferase gene mutations in an unusual Crigler-Najjar syndrome patient. Mol Med Rep. 2012 Sep. 6(3):667-9. [Medline].

  23. Ostanek B, Furlan D, Mavec T, Lukac-Bajalo J. UGT1A1(TA)n promoter polymorphism--a new case of a (TA)8 allele in Caucasians. Blood Cells Mol Dis. 2007 Mar-Apr. 38(2):78-82. [Medline].

  24. Papez MJ, Civalier CJ, Thorne LB, Gulley ML. UGT1A1 promoter genotype is not strongly associated with severity of coronary artery disease. Diagn Mol Pathol. 2009 Dec. 18(4):226-31. [Medline].

  25. Tapan S, Dogru T, Tasci I, Ercin CN, Ozgurtas T, Erbil MK. Soluble CD40 ligand and soluble P-selectin levels in Gilbert's syndrome: a link to protection against atherosclerosis?. Clin Biochem. 2009 Jun. 42(9):791-5. [Medline].

  26. Ferraris A, D'Amato G, Nobili V, Torres B, Marcellini M, Dallapiccola B. Combined test for UGT1A1 -3279T-->G and A(TA)nTAA polymorphisms best predicts Gilbert's syndrome in Italian pediatric patients. Genet Test. 2006 Summer. 10(2):121-5. [Medline].

  27. Hsieh TY, Shiu TY, Huang SM, Lin HH, Lee TC, Chen PJ, et al. Molecular pathogenesis of Gilbert's syndrome: decreased TATA-binding protein binding affinity of UGT1A1 gene promoter. Pharmacogenet Genomics. 2007 Apr. 17(4):229-36. [Medline].

  28. Petit FM, Hébert M, Gajdos V, Mollet-Boudjemline A, Labrune P. Comments on seven novel mutations of the UGT1A1 gene in patients with unconjugated hyperbilirubinemia by D'Apolito et al. Haematologica. 2007 Jul. 92(7):e80. [Medline].

  29. Rigato I, Cravatari M, Avellini C, Ponte E, Crocè SL, Tiribelli C. Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1. Nat Clin Pract Gastroenterol Hepatol. 2007 Jul. 4(7):403-8. [Medline].

  30. Teng HC, Huang MJ, Tang KS, Yang SS, Tseng CS, Huang CS. Combined UGT1A1 and UGT1A7 variant alleles are associated with increased risk of Gilbert's syndrome in Taiwanese adults. Clin Genet. 2007 Oct. 72(4):321-8. [Medline].

  31. Ehmer U, Lankisch TO, Erichsen TJ, Kalthoff S, Freiberg N, Wehmeier M, et al. Rapid allelic discrimination by TaqMan PCR for the detection of the Gilbert's syndrome marker UGT1A1*28. J Mol Diagn. 2008 Nov. 10(6):549-52. [Medline]. [Full Text].

  32. Sneitz N, Bakker CT, de Knegt RJ, Halley DJ, Finel M, Bosma PJ. Crigler-Najjar syndrome in The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants. Hum Mutat. 2010 Jan. 31(1):52-9. [Medline].

  33. Canu G, Minucci A, Zuppi C, Capoluongo E. Gilbert and Crigler Najjar syndromes: An update of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene mutation database. Blood Cells Mol Dis. 2013 Apr. 50(4):273-80. [Medline].

  34. Fang JL, Lazarus P. Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol Biomarkers Prev. 2004 Jan. 13(1):102-9. [Medline].

  35. Farheen S, Sengupta S, Santra A, Pal S, Dhali GK, Chakravorty M, et al. Gilbert's syndrome: High frequency of the (TA)7 TAA allele in India and its interaction with a novel CAT insertion in promoter of the gene for bilirubin UDP-glucuronosyltransferase 1 gene. World J Gastroenterol. 2006 Apr 14. 12(14):2269-75. [Medline].

  36. Jirsa M, Petrasek J, Vitek L. Linkage between A(TA)7TAA and -3279T>G mutations in UGT1A1 is not essential for pathogenesis of Gilbert syndrome. Liver Int. 2006 Dec. 26(10):1302-3. [Medline].

  37. Maruo Y, D'Addario C, Mori A, Iwai M, Takahashi H, Sato H, et al. Two linked polymorphic mutations (A(TA)7TAA and T-3279G) of UGT1A1 as the principal cause of Gilbert syndrome. Hum Genet. 2004 Nov. 115(6):525-6. [Medline].

  38. Tzetis M, Kanavakis E, Tsezou A, Ladis V, Pateraki E, Georgakopoulou T, et al. Gilbert syndrome associated with beta-thalassemia. Pediatr Hematol Oncol. 2001 Dec. 18(8):477-84. [Medline].

  39. Seo YS, Keum B, Park S, Kim du R, Kwon YD, Kim YS, et al. Gilbert's syndrome phenotypically expressed as Crigler-Najjar syndrome type II. Scand J Gastroenterol. 2007 Apr. 42(4):540-1. [Medline].

  40. Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO. Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics. 2007 Dec. 17(12):1017-29. [Medline].

  41. Huang CS, Huang MJ, Lin MS, Yang SS, Teng HC, Tang KS. Genetic factors related to unconjugated hyperbilirubinemia amongst adults. Pharmacogenet Genomics. 2005 Jan. 15(1):43-50. [Medline].

  42. Origa R, Galanello R, Perseu L, Tavazzi D, Domenica Cappellini M, Terenzani L, et al. Cholelithiasis in thalassemia major. Eur J Haematol. 2009 Jan. 82(1):22-5. [Medline].

  43. Tsezou A, Tzetis M, Giannatou E, Spanos I, Roma E, Fretzayas A, et al. Gilbert syndrome as a predisposing factor for cholelithiasis risk in the Greek adult population. Genet Test Mol Biomarkers. 2009 Feb. 13(1):143-6. [Medline].

  44. Clementi M, Di Gianantonio E, Fabris L, Forabosco P, Strazzabosco M, Tenconi R, et al. Inheritance of hyperbilirubinemia: evidence for a major autosomal recessive gene. Dig Liver Dis. 2007 Apr. 39(4):351-5. [Medline].

  45. Manning D, Todd P, Maxwell M, Jane Platt M. Prospective surveillance study of severe hyperbilirubinaemia in the newborn in the UK and Ireland. Arch Dis Child Fetal Neonatal Ed. 2007 Sep. 92(5):F342-6. [Medline]. [Full Text].

  46. Sagili H, Pramya N, Jayalaksmi D, Rani R. Crigler-Najjar syndrome II and pregnancy outcome. J Obstet Gynaecol. 2012 Feb. 32(2):188-9. [Medline].

  47. Kaneko J, Sugawara Y, Maruo Y, Sato H, Tamura S, Imamura H, et al. Liver transplantation using donors with Gilbert syndrome. Transplantation. 2006 Jul 27. 82(2):282-5. [Medline].

  48. Yilmaz M, Unal B, Isik B, Ozgor D, Piskin T, Ersan V, et al. Can an extended right lobe be harvested from a donor with Gilbert's syndrome for living-donor liver transplantation? Case report. Transplant Proc. 2012 Jul-Aug. 44(6):1640-3. [Medline].

  49. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. 2006 Oct 3. 114(14):1476-81. [Medline].

  50. Lin JP, Schwaiger JP, Cupples LA, O'Donnell CJ, Zheng G, Schoenborn V, et al. Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene for anti-atherogenic serum bilirubin levels--the Framingham Heart Study. Atherosclerosis. 2009 Sep. 206(1):228-33. [Medline]. [Full Text].

  51. Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, et al. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome. Circulation. 2012 Jul 31. 126(5):598-603. [Medline].

  52. Vítek L, Schwertner HA. Protective effects of serum bilirubin on peripheral vascular disease. Ann Hepatol. 2008 Jan-Mar. 7(1):94-5. [Medline].

  53. Schwertner HA, Vítek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis. 2008 May. 198(1):1-11. [Medline].

  54. Strassburg CP. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics. 2008 Jun. 9(6):703-15. [Medline].

  55. Lankisch TO, Behrens G, Ehmer U, Möbius U, Rockstroh J, Wehmeier M, et al. Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy--an extended haplotype of genetic variants increases risk in indinavir treatment. J Hepatol. 2009 May. 50(5):1010-8. [Medline].

  56. Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev. 2008 Nov. 34(7):656-69. [Medline].

  57. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004 Jul. 114 (1):297-316. [Medline].

  58. Cakmak A, Calik M, Atas A, Hirfanoglu I, Erel O. Can haptoglobin be an indicator for the early diagnosis of neonatal jaundice?. J Clin Lab Anal. 2008. 22(6):409-14. [Medline].

  59. Esteban A, Pérez-Mateo M. Heterogeneity of paracetamol metabolism in Gilbert's syndrome. Eur J Drug Metab Pharmacokinet. 1999 Jan-Mar. 24(1):9-13. [Medline].

  60. Rauchschwalbe SK, Zühlsdorf MT, Wensing G, Kuhlmann J. Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype. Int J Clin Pharmacol Ther. 2004 Feb. 42(2):73-7. [Medline].

  61. Birraux J, Menzel O, Wildhaber B, Jond C, Nguyen TH, Chardot C. A step toward liver gene therapy: efficient correction of the genetic defect of hepatocytes isolated from a patient with Crigler-Najjar syndrome type 1 with lentiviral vectors. Transplantation. 2009 Apr 15. 87(7):1006-12. [Medline].

  62. Miranda PS, Bosma PJ. Towards liver-directed gene therapy for Crigler-Najjar syndrome. Curr Gene Ther. 2009 Apr. 9(2):72-82. [Medline].

  63. Sherbiny HS, Youssef DM, Sherbini AS, El-Behedy R, Sherief LM. High-intensity light-emitting diode vs fluorescent tubes for intensive phototherapy in neonates. Paediatr Int Child Health. 2016 May. 36 (2):127-33. [Medline].

  64. Waterham M, Bhatia R, Donath S, Molesworth C, Tan K, Stewart M. Phototherapy in transport for neonates with unconjugated hyperbilirubinaemia. J Paediatr Child Health. 2016 Jan. 52 (1):67-71. [Medline].

  65. Karakukcu C, Ustdal M, Ozturk A, Baskol G, Saraymen R. Assessment of DNA damage and plasma catalase activity in healthy term hyperbilirubinemic infants receiving phototherapy. Mutat Res. 2009 Nov-Dec. 680(1-2):12-6. [Medline].

  66. Ramy N, Ghany EA, Alsharany W, et al. Jaundice, phototherapy and DNA damage in full-term neonates. J Perinatol. 2015 Nov 19. [Medline].

  67. Kumar P, Chawla D, Deorari A. Light-emitting diode phototherapy for unconjugated hyperbilirubinaemia in neonates. Cochrane Database Syst Rev. 2011 Dec 7. CD007969. [Medline].

  68. Schauer R, Stangl M, Lang T, Zimmermann A, Chouker A, Gerbes AL, et al. Treatment of Crigler-Najjar type 1 disease: relevance of early liver transplantation. J Pediatr Surg. 2003 Aug. 38(8):1227-31. [Medline].

  69. van der Veere CN, Sinaasappel M, McDonagh AF, Rosenthal P, Labrune P, Odièvre M, et al. Current therapy for Crigler-Najjar syndrome type 1: report of a world registry. Hepatology. 1996 Aug. 24(2):311-5. [Medline].

  70. Lysy PA, Najimi M, Stephenne X, Bourgois A, Smets F, Sokal EM. Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives. World J Gastroenterol. 2008 Jun 14. 14(22):3464-70. [Medline]. [Full Text].

  71. Ozçay F, Alehan F, Sevmis S, Karakayali H, Moray G, Torgay A, et al. Living related liver transplantation in Crigler-Najjar syndrome type 1. Transplant Proc. 2009 Sep. 41(7):2875-7. [Medline].

  72. Ambrosino G, Varotto S, Strom SC, Guariso G, Franchin E, Miotto D, et al. Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell Transplant. 2005. 14(2-3):151-7. [Medline].

  73. Fox IJ, Chowdhury JR. Hepatocyte transplantation. Am J Transplant. 2004. 4 Suppl 6:7-13. [Medline].

  74. Fox IJ, Chowdhury JR, Kaufman SS, Goertzen TC, Chowdhury NR, Warkentin PI, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med. 1998 May 14. 338(20):1422-6. [Medline].

  75. Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis. 2006 Apr-Jun. 29(2-3):431-5. [Medline].

  76. Ribes-Koninckx C, Pareja Ibars E, Agrasot MA, Bonora-Centelles A, Polo Miquel B, Vila Carbó JJ, et al. Clinical outcome of hepatocyte transplantation in four pediatric patients with inherited metabolic diseases. Cell Transplant. 2012 Apr 18. [Medline].

  77. Palmela I, Correia L, Silva RF, et al. Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro study. Front Neurosci. 2015. 9:80. [Medline].

  78. Woodgate P, Jardine LA. Neonatal jaundice: phototherapy. BMJ Clin Evid. 2015 May 22. 2015:[Medline].

 
Previous
Next
 
Production of bilirubin.
Enterohepatic circulation of bilirubin.
Conjugation of bilirubin.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.